LIXTE BIOTECHNOLOGY HOLDINGS, INC. financial data

Symbol
LIXT on Nasdaq
Location
Boca Raton, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 594% % -55%
Return On Equity -216% % -45%
Return On Assets -176% % -35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,704,200 shares 154%
Common Stock, Shares, Outstanding 5,704,200 shares 154%
Entity Public Float $5,195,000 USD 362%
Common Stock, Value, Issued $570 USD 153%
Weighted Average Number of Shares Outstanding, Basic 6,171,195 shares 174%
Weighted Average Number of Shares Outstanding, Diluted 6,171,195 shares 174%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $237,631 USD -72%
General and Administrative Expense $3,658,969 USD -28%
Operating Income (Loss) $3,896,600 USD 2.2%
Net Income (Loss) Attributable to Parent $4,083,320 USD -2.1%
Earnings Per Share, Basic -1 USD/shares 29%
Earnings Per Share, Diluted -1 USD/shares 29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,414,263 USD -16%
Assets, Current $5,433,676 USD 222%
Assets $5,433,676 USD 220%
Liabilities, Current $521,422 USD 59%
Retained Earnings (Accumulated Deficit) $55,533,319 USD -7.9%
Stockholders' Equity Attributable to Parent $4,912,254 USD 259%
Liabilities and Equity $5,433,676 USD 220%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $568,483 USD 28%
Net Cash Provided by (Used in) Financing Activities $914,228 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 5,704,200 shares 154%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $345,745 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $3,135 USD -56%
Deferred Tax Assets, Valuation Allowance $12,617,000 USD 7.9%
Deferred Tax Assets, Gross $12,617,000 USD 7.9%
Deferred Tax Assets, Operating Loss Carryforwards $9,515,000 USD 11%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $57,891,644 USD 17%
Share-based Payment Arrangement, Expense $1,222,325 USD 175%
Interest Expense $9,834 USD -56%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%